## Intended Results / Panel Composition

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>ASPDNA18S-01</td>
<td>Aspergillus fumigatus</td>
<td>Synthetic sputum</td>
<td>DS2_2</td>
<td>Detected</td>
<td>CORE</td>
<td>88.2</td>
</tr>
<tr>
<td>ASPDNA18S-02</td>
<td>Aspergillus fumigatus</td>
<td>Synthetic sputum</td>
<td>DS2_1</td>
<td>Frequently Detected</td>
<td>CORE</td>
<td>100.0</td>
</tr>
<tr>
<td>ASPDNA18S-03</td>
<td>Aspergillus niger</td>
<td>Synthetic sputum</td>
<td>DS3_1</td>
<td>Detected</td>
<td>EDUCATIONAL</td>
<td>86.3</td>
</tr>
<tr>
<td>ASPDNA18S-04</td>
<td>Negative</td>
<td>Synthetic sputum</td>
<td>-</td>
<td>Negative</td>
<td>CORE</td>
<td>90.2</td>
</tr>
<tr>
<td>ASPDNA18S-05</td>
<td>Aspergillus niger</td>
<td>Synthetic sputum</td>
<td>DS3_2</td>
<td>Detected</td>
<td>EDUCATIONAL</td>
<td>86.3</td>
</tr>
<tr>
<td>ASPDNA18S-06</td>
<td>Negative</td>
<td>Plasma</td>
<td>-</td>
<td>Negative</td>
<td>CORE</td>
<td>96.1</td>
</tr>
<tr>
<td>ASPDNA18S-07</td>
<td>Aspergillus fumigatus</td>
<td>Plasma</td>
<td>DS1_1</td>
<td>Frequently Detected</td>
<td>CORE</td>
<td>98.0</td>
</tr>
<tr>
<td>ASPDNA18S-08</td>
<td>Aspergillus fumigatus</td>
<td>Plasma</td>
<td>DS1_2</td>
<td>Detected</td>
<td>CORE</td>
<td>94.1</td>
</tr>
</tbody>
</table>

[1] **Sample Relationships**: Indicates the relationships of the samples within this challenge. The highest titre member of dilution series DS1 is indicated by DS1_1 and further members of the series as DS1_2, DS1_3 etc. in order of reducing titre. Additional dilution series are indicated by DS2 (e.g. DS2_1, DS2_2 etc.), DS3 (e.g. DS3_1, DS3_2 etc.). If one duplicate pair is present this is indicated by 'D1'. Further duplicate pairs are indicated by 'D2', 'D3' etc.

[2] **Detection Frequency**: To aid qualitative analysis each panel member is assigned a frequency of detection. This is based on the peer group consensus of all qualitative results returned from participants within the EQA challenge / distribution.

[3] **Sample Status**: EQA samples are defined as "CORE" or "EDUCATIONAL". Core proficiency samples are reviewed by the QCMD Scientific Expert(s). This is on the basis of scientific information, clinical relevance, current literature and, where appropriate, professional clinical guidelines. Participating laboratories are expected to report core proficiency samples correctly within the EQA challenge / distribution.

[4] **Percentage Correct (All)**: Percentage of datasets (%) reporting the correct qualitative result and the total number of datasets (n) reported for each panel member.

---

**For further details please refer to the current participant manual.**

---

### Your Summary Results

**EQA Assessment Group [1]**

<table>
<thead>
<tr>
<th>Core Panel Detection (Qualitative) Score [2]</th>
<th>Commercial</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## Core Panel Members Results

<table>
<thead>
<tr>
<th>Sample Code</th>
<th>Qualitative Results</th>
<th>Your Quantitative Data (for information only)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Percentage Correct (All) [4]</td>
<td>Reported Value</td>
</tr>
<tr>
<td>ASPDNA18S-01</td>
<td>88.2 Positive</td>
<td>3</td>
</tr>
<tr>
<td>ASPDNA18S-02</td>
<td>100.0 Positive</td>
<td>3</td>
</tr>
<tr>
<td>ASPDNA18S-04</td>
<td>90.2 Negative</td>
<td>3</td>
</tr>
<tr>
<td>ASPDNA18S-06</td>
<td>96.1 Negative</td>
<td>3</td>
</tr>
<tr>
<td>ASPDNA18S-07</td>
<td>98.0 Positive</td>
<td>3</td>
</tr>
<tr>
<td>ASPDNA18S-08</td>
<td>94.1 Positive</td>
<td>3</td>
</tr>
</tbody>
</table>

[1] **EQA Assessment Group:** To aid data analysis, participant results are grouped according to the molecular amplification/detection method specified within their molecular workflow for this challenge / distribution. For further details refer to the Additional Information: Individual Panel Member Analysis section of this report.

[2] **Core Panel Detection (Qualitative) Score:** An overall core panel detection score provided per challenge / distribution.

[3] **Quantitative Data (for information only):** This is the quantitative value, unitage and cycle threshold you provided when you submitted your results. For qualitative programmes this information is not used as part of your formal EQA assessment.

[4] **Percentage Correct (All):** Percentage of datasets (%) reporting the correct qualitative results for each panel member.

[5] **Your Result:** The qualitative result you reported for each sample within this EQA challenge / distribution.

[6] **Detection Score:** Your detection (qualitative) scores are based on the assigned detection frequency of each panel members, where 0 (zero) is "highly satisfactory" and 3 (three) is "highly unsatisfactory". Scores are provided for individual panel members.

*For further details please refer to the current participant manual.*

### Core Panel Member Score Breakdown

![core_panel_score_breakdown](image)

- **Number of Datasets**
- **Cumulative Percentage**
- **My Score**
Core Panel Member Score Breakdown - Detection: This figure gives you a breakdown of the qualitative detection scores for all qualitative datasets returned within this EQA challenge / distribution independent of the EQA assessment group. Panel detection scores are generated from only those panel members that are defined as "CORE". For further details please refer to the current participant manual.

My Workflow Details
The details of the workflow(s) used to submit your results for this challenge.

Name
Aspergillus PCR Kit (v3)

Assays
Extraction - Manual Extraction Process
- Commercial
  - Kit Manufacturer: GeneProof
  - Kit Type: PathoegenFree DNA Isolation Kit

Amplification - GeneProof - croBEE Real-Time PCR System
- Commercial
  - Kit Manufacturer: GeneProof
  - Kit Type: Aspergillus PCR Kit
  - Kit Version: ISEX

Educational Panel Members Results

<table>
<thead>
<tr>
<th>Sample Code</th>
<th>Qualitative Results</th>
<th>Your Quantitative Data (for information only)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASPDNA18S-03</td>
<td>86.3</td>
<td>Positive</td>
</tr>
<tr>
<td>ASPDNA18S-05</td>
<td>86.3</td>
<td>Positive</td>
</tr>
</tbody>
</table>

[1] Quantitative Data (for information only): This is the quantitative value, unitage and cycle threshold you provided when you submitted your results. For qualitative programmes this information is not used as part of your formal EQA assessment.

[2] Percentage Correct (All): Percentage of datasets (%) reporting the correct qualitative results for each panel member.

[3] Your Result: The qualitative result you reported for each sample within this EQA challenge / distribution.

[4] Detection Score: Your detection (qualitative) scores are based on the assigned detection frequency of each panel member, where 0 (zero) is "highly satisfactory" and 3 (three) is "highly unsatisfactory". Scores are provided for individual panel members.

For further details please refer to the current participant manual.
Further Programme Details

Number of Participants

Number of Countries

Number of Respondents

Number of Datasets Submitted

Qualitative Results Returned

EQA Programme Aims

To assess the qualitative detection of Aspergillus species at different concentrations.

Feedback and Enquiries

Participants are encouraged to read the QCMD Participants' Manual, which can be downloaded from the QCMD website.

Any queries about this report should be addressed to the QCMD Neutral Office (neutraloffice@qcmd.org).
Panel member analysis is separated into CORE samples followed by EDUCATIONAL samples.

**Additional Core Samples Information**

The following section has been categorised as shown below:

**Core ► Qualitative**

**Individual Panel Member Analysis (Qualitative)**

Qualitative analysis for each panel member is provided in relation to your EQA assessment group. EQA assessment groups are established using the molecular workflow information reported by all participants within this EQA challenge / distribution. The principal level of assessment is at the individual method level which is defined based on your reported "amplification/detection method" and other laboratories using the same or similar amplification/detection methods.

To allow meaningful assessment at the individual method level the EQA assessment group must consist of 5 or more datasets. If there are not sufficient datasets at the individual method level then your results will be included within a higher EQA assessment group based on whether it is a commercial or in house technology/method. The highest level assessment grouping is "All" participant reported qualitative results.

A breakdown of qualitative results reported by participants on each of the panel members within this EQA challenge / distribution is provided below. You can compare your results to those within your EQA assessment group and those obtained within other EQA assessment groups or to the overall consensus for each sample within this EQA challenge / distribution.

**ASPDNA18S-01 - Qualitative Results Breakdown**

<table>
<thead>
<tr>
<th>Sample Code</th>
<th>Sample Content</th>
<th>Matrix</th>
<th>Sample Relationships</th>
<th>Detection Frequency</th>
<th>Sample Status</th>
<th>Percentage Correct (All)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASPDNA18S-01</td>
<td>Aspergillus fumigatus</td>
<td>Synthetic sputum</td>
<td>DS2_2</td>
<td>Detected</td>
<td>CORE</td>
<td>88.2%</td>
</tr>
</tbody>
</table>

Number of Values in Groups

- **All**: 51
- **Commercial**: 19
- **In-House**: 32
  - **Real-time In-House PCR**: 29

Incorrect ▼ Correct
Individual Report

QCMD 2018 Aspergillus spp. DNA EQA Programme

Catalogue Code: QAF104140
Ref Code: ASPDNA18
Challenge: S
Analysis Type: Qualitative
Dataset: 235499
Report UID: 2677/235499/1641
Laboratory CZ023

Groups below n=5:
- Bio-Evolution (n=1), Bio-Evolution - Bio-Evolution Real Time PCR (n=1), Bruker (n=3), Bruker - Bruker Real Time PCR (n=3), Chipron (n=1), Chipron - Chipron LCD Array (n=1), ELITech Group (n=4), ELITech Group - Elitech Elite Real Time kit (n=4), GeneProof (n=1), GeneProof - GeneProof Real Time PCR kit (n=1), OLM Diagnostics (n=1), OLM Diagnostics - OLM Dx Real Time PCR (n=1), PathoNostics (n=4), PathoNostics - PathoNostics Genius (n=4), QIAGEN (n=2), QIAGEN - QIAGEN Artus Real Time (n=2), Roche (n=1), Roche - Roche LightCycler (n=1), generi biotech (n=1), generi biotech - gb Real Time PCR (n=1), In-House - Conventional In-House PCR (n=3)

Groups Rolled Up:

ASPDNA18S-02 - Qualitative Results Breakdown

<table>
<thead>
<tr>
<th>Sample Code</th>
<th>Sample Content</th>
<th>Matrix</th>
<th>Sample Relationships</th>
<th>Detection Frequency</th>
<th>Sample Status</th>
<th>Percentage Correct (All)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASPDNA18S-02</td>
<td>Aspergillus fumigatus</td>
<td>Synthetic sputum</td>
<td>DS2_1</td>
<td>Frequently Detected</td>
<td>CORE</td>
<td>100.0</td>
</tr>
</tbody>
</table>

![Bar chart showing the number of values in groups for Incorrect and Correct results.]

Groups below n=5:
- Bio-Evolution (n=1), Bio-Evolution - Bio-Evolution Real Time PCR (n=1), Bruker (n=3), Bruker - Bruker Real Time PCR (n=3), Chipron (n=1), Chipron - Chipron LCD Array (n=1), ELITech Group (n=4), ELITech Group - Elitech Elite Real Time kit (n=4), GeneProof (n=1), GeneProof - GeneProof Real Time PCR kit (n=1), OLM Diagnostics (n=1), OLM Diagnostics - OLM Dx Real Time PCR (n=1), PathoNostics (n=4), PathoNostics - PathoNostics Genius (n=4), QIAGEN (n=2), QIAGEN - QIAGEN Artus Real Time (n=2), Roche (n=1), Roche - Roche LightCycler (n=1), generi biotech (n=1), generi biotech - gb Real Time PCR (n=1), In-House - Conventional In-House PCR (n=3)

Groups Rolled Up:
ASPDNA18S-04 - Qualitative Results Breakdown

<table>
<thead>
<tr>
<th>Sample Code</th>
<th>Sample Content</th>
<th>Matrix</th>
<th>Sample Relationships</th>
<th>Detection Frequency</th>
<th>Sample Status</th>
<th>Percentage Correct (All)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASPDNA18S-04</td>
<td>Negative</td>
<td>Synthetic sputum</td>
<td>-</td>
<td>Negative</td>
<td>CORE</td>
<td>90.2</td>
</tr>
</tbody>
</table>

**Groups below n=5:** Bio-Evolution (n=1), Bio-Evolution - Bio-Evolution Real Time PCR (n=1), Bruker (n=3), Bruker - Bruker Real Time PCR (n=3), Chipron (n=1), Chipron - Chipron LCD Array (n=1), ELITech Group (n=4), ELITech Group - Elitech Elite Real Time kit (n=4), GeneProof (n=1), GeneProof - GeneProof Real Time PCR kit (n=1), OLM Diagnostics (n=1), OLM Diagnostics - OLM Dx Real Time PCR (n=1), PathoNostics (n=4), PathoNostics - PathoNostics Genius (n=4), QIAGEN (n=2), QIAGEN - QIAGEN Artus Real Time (n=2), Roche (n=1), Roche - Roche LightCycler (n=1), generi biotech (n=1), generi biotech - gb Real Time PCR (n=1), In-House - Conventional In-House PCR (n=3)

**Groups Rolled Up:**

- Commercial
- In-House
  - Real-time In-House PCR

---

**Number of Values in Groups**

- Incorrect: 51
- Correct: 19
- 0% Incorrect: 51 values
- 20% Incorrect: 19 values
- 40% Incorrect: 32 values
- 60% Incorrect: 29 values
- 80% Incorrect: 0 values
- 100% Incorrect: 0 values

---

QCMD, Technology Terrace, Todd Campus, West of Scotland Science Park, Glasgow, G20 0XA Tel: +44 (0) 141 945 6674, Fax: +44 (0) 141 945 5795 Web: www.qcmd.org

Page 7 of 13  Issue Date: 29 Oct 2018 Report authorised by the QCMD Executive (1) A UKAS accredited proficiency testing provider No.4385
### ASPDNA18S-06 - Qualitative Results Breakdown

<table>
<thead>
<tr>
<th>Sample Code</th>
<th>Sample Content</th>
<th>Matrix</th>
<th>Sample Relationships</th>
<th>Detection Frequency</th>
<th>Sample Status</th>
<th>Percentage Correct (All)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASPDNA18S-06</td>
<td>Negative</td>
<td>Plasma</td>
<td>-</td>
<td>Negative</td>
<td>CORE</td>
<td>96.1 %</td>
</tr>
</tbody>
</table>

#### Groups below n=5:
- Bio-Evolution (n=1), Bio-Evolution - Bio-Evolution Real Time PCR (n=1), Bruker (n=3), Bruker - Bruker Real Time PCR (n=3), Chipron (n=1), Chipron - Chipron LCD Array (n=1), ELITech Group (n=4), ELITech Group - Elitech Elite Real Time kit (n=4), GeneProof (n=1), GeneProof - GeneProof Real Time PCR kit (n=1), OLM Diagnostics (n=1), OLM Diagnostics - OLM Dx Real Time PCR (n=1), PathoNostics (n=4), PathoNostics - PathoNostics Genius (n=4), QIAGEN (n=2), QIAGEN - QIAGEN Artus Real Time (n=2), Roche (n=1), Roche - Roche LightCycler (n=1), generi biotech (n=1), generi biotech - gb Real Time PCR (n=1), In-House - Conventional In-House PCR (n=3)

#### Groups Rolled Up:
- Incorrect: 51
- Correct: 19
- 32
- 29

---

QCMD, Technology Terrace, Todd Campus, West of Scotland Science Park, Glasgow, G20 0XA Tel: +44 (0) 141 945 6474, Fax: +44 (0) 141 945 5795 Web: www.qcmd.org

Page 8 of 13

Issue Date: 29 Oct 2018

Report authorised by the QCMD Executive (1)

A UKAS accredited proficiency testing provider No.4385
### ASPDNA18S-07 - Qualitative Results Breakdown

<table>
<thead>
<tr>
<th>Sample Code</th>
<th>Sample Content</th>
<th>Matrix</th>
<th>Sample Relationships</th>
<th>Detection Frequency</th>
<th>Sample Status</th>
<th>Percentage Correct (All)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASPDNA18S-07</td>
<td><em>Aspergillus fumigatus</em></td>
<td>Plasma</td>
<td>DS1_1</td>
<td>Frequently Detected</td>
<td>CORE</td>
<td>98.0%</td>
</tr>
</tbody>
</table>

- **Groups below n=5:** Bio-Evolution (n=1), Bio-Evolution - Bio-Evolution Real Time PCR (n=1), Bruker (n=3), Bruker - Bruker Real Time PCR (n=3), Chipron (n=1), Chipron - Chipron LCD Array (n=1), ELITech Group (n=4), ELITech Group - Eli tech Elite Real Time kit (n=4), GeneProof (n=1), GeneProof - GeneProof Real Time PCR kit (n=1), OLM Diagnostics (n=1), OLM Diagnostics - OLM Dx Real Time PCR (n=1), PathoNostics (n=4), PathoNostics - PathoNostics Genius (n=4), QIAGEN (n=2), QIAGEN - QIAGEN Artus Real Time (n=2), Roche (n=1), Roche - Roche LightCycler (n=1), generi biotech (n=1), generi biotech - gb Real Time PCR (n=1), In-House - Conventional In-House PCR (n=3)

- **Groups Rolled Up:**
ASPDNA18S-08 - Qualitative Results Breakdown

<table>
<thead>
<tr>
<th>Sample Code</th>
<th>Sample Content</th>
<th>Matrix</th>
<th>Sample Relationships</th>
<th>Detection Frequency</th>
<th>Sample Status</th>
<th>Percentage Correct (All)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASPDNA18S-08</td>
<td>Aspergillus fumigatus</td>
<td>Plasma</td>
<td>DS1_2</td>
<td>Detected</td>
<td>CORE</td>
<td>94.1</td>
</tr>
</tbody>
</table>

Groups below n=5: Bio-Evolution (n=1), Bio-Evolution - Bio-Evolution Real Time PCR (n=1), Bruker (n=3), Bruker - Bruker Real Time PCR (n=3), Chipron (n=1), Chipron - Chipron LCD Array (n=1), ELITech Group (n=4), ELITech Group - Elitech Elite Real Time kit (n=4), GeneProof (n=1), GeneProof - GeneProof Real Time PCR kit (n=1), OLM Diagnostics (n=1), OLM Diagnostics - OLM Dx Real Time PCR (n=1), PathoNostics (n=4), PathoNostics - PathoNostics Genius (n=4), QIAGEN (n=2), QIAGEN - QIAGEN Artus Real Time (n=2), Roche (n=1), Roche - Roche LightCycler (n=1), generi biotech (n=1), generi biotech - gb Real Time PCR (n=1), In-House - Conventional In-House PCR (n=3)

Groups Rolled Up:
Additional Educational Samples Information

The following section has been categorised as shown below:

Educational ▶ Qualitative

Individual Panel Member Analysis (Qualitative)

Qualitative analysis for each panel member is provided in relation to your EQA assessment group. EQA assessment groups are established using the molecular workflow information reported by all participants within this EQA challenge / distribution. The principal level of assessment is at the individual method level which is defined based on your reported "amplification/detection method" and other laboratories using the same or similar amplification/detection methods.

To allow meaningful assessment at the individual method level the EQA assessment group must consist of 5 or more datasets. If there are not sufficient datasets at the individual method level then your results will be included within a higher EQA assessment group based on whether it is a commercial or in house technology/method. The highest level assessment grouping is "All" participant reported qualitative results.

A breakdown of qualitative results reported by participants on each of the panel members within this EQA challenge / distribution is provided below. You can compare your results to those within your EQA assessment group and those obtained within other EQA assessment groups or to the overall consensus for each sample within this EQA challenge / distribution.

ASPDNA18S-03 - Qualitative Results Breakdown

<table>
<thead>
<tr>
<th>Sample Code</th>
<th>Sample Content</th>
<th>Matrix</th>
<th>Sample Relationships</th>
<th>Detection Frequency</th>
<th>Sample Status</th>
<th>Percentage Correct (All)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASPDNA18S-03</td>
<td>Aspergillus niger</td>
<td>Synthetic sputum</td>
<td>DS3_1</td>
<td>Detected</td>
<td>EDUCATIONAL</td>
<td>86.3</td>
</tr>
</tbody>
</table>

Number of Values in Groups

- Incorrect
- Correct

QCMD, Technology Terrace, Todd Campus, West of Scotland Science Park, Glasgow, G20 0XA Tel: +44 (0) 141 945 6474, Fax: +44 (0) 141 945 5795 Web: www.qcmd.org

Page 11 of 13
Issue Date: 29 Oct 2018
Report authorised by the QCMD Executive (1)
A UKAS accredited proficiency testing provider No.4385
### Groups below n=5:
- Bio-Evolution (n=1), Bio-Evolution - Bio-Evolution Real Time PCR (n=1), Bruker (n=3), Bruker - Bruker Real Time PCR (n=3), Chipron (n=1), Chipron - Chipron LCD Array (n=1), ELITech Group (n=4), ELITech Group - Elitech Elite Real Time kit (n=4), GeneProof (n=1), GeneProof - GeneProof Real Time PCR kit (n=1), OLM Diagnostics (n=1), OLM Diagnostics - OLM Dx Real Time PCR (n=1), PathoNostics (n=4), PathoNostics - PathoNostics Genius (n=4), QIAGEN (n=2), QIAGEN - QIAGEN Artus Real Time (n=2), Roche (n=1), Roche - Roche LightCycler (n=1), generi biotech (n=1), generi biotech - gb Real Time PCR (n=1), In-House - Conventional In-House PCR (n=3)

### Groups Rolled Up:

#### ASPDNA18S-05 - Qualitative Results Breakdown

<table>
<thead>
<tr>
<th>Sample Code</th>
<th>Sample Content</th>
<th>Matrix</th>
<th>Sample Relationships</th>
<th>Detection Frequency</th>
<th>Sample Status</th>
<th>Percentage Correct (All)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASPDNA18S-05</td>
<td>Aspergillus niger</td>
<td>Synthetic sputum</td>
<td>DS3_2</td>
<td>Detected</td>
<td>EDUCATIONAL</td>
<td>86.3</td>
</tr>
</tbody>
</table>

![Bar chart showing detection frequency and percentage correct values for different categories: Commercial and In-House, with real-time In-House PCR highlighted.](image)

#### Groups Rolled Up:

- Bio-Evolution (n=1), Bio-Evolution - Bio-Evolution Real Time PCR (n=1), Bruker (n=3), Bruker - Bruker Real Time PCR (n=3), Chipron (n=1), Chipron - Chipron LCD Array (n=1), ELITech Group (n=4), ELITech Group - Elitech Elite Real Time kit (n=4), GeneProof (n=1), GeneProof - GeneProof Real Time PCR kit (n=1), OLM Diagnostics (n=1), OLM Diagnostics - OLM Dx Real Time PCR (n=1), PathoNostics (n=4), PathoNostics - PathoNostics Genius (n=4), QIAGEN (n=2), QIAGEN - QIAGEN Artus Real Time (n=2), Roche (n=1), Roche - Roche LightCycler (n=1), generi biotech (n=1), generi biotech - gb Real Time PCR (n=1), In-House - Conventional In-House PCR (n=3)
QCMD 2018 Aspergillus spp. DNA EQA Programme

Catalogue Code: QAF104140
Ref Code: ASPDNA18
Challenge: S
Analysis Type: Qualitative
Dataset: 235499
Report UID: 2677/235499/1641
Laboratory CZ023

QCMD © 2018. The QCMD EQA programme samples, associated reports and data generated during this programme are intended for External Quality Assessment (EQA) and Proficiency Testing (PT) purposes only. QCMD operates according to a strict Code of Practice which is in line with ISO/IEC 17043 and associated standards. Data reported in QCMD programmes is representative of a laboratory’s standard diagnostic testing protocols irrespective of the technology they use. The data provided in the reports are based on technical information provided by the individual laboratories as part of the assessment process, as such it does not constitute a formal technology method comparison. All text and images produced by QCMD are the property of QCMD unless otherwise stated.

The reproduction and use of these materials is not permitted without the express written consent of QCMD. The use of the information provided in QCMD reports for commercial purposes is strictly prohibited.